摘要
非小细胞肺癌是肺癌中最常见组织学类型,是发病率、死亡率均较高的恶性肿瘤。晚期非小细胞肺癌一线治疗后,为稳定病情在耐药产生前进行化疗药物或靶向药物维持治疗,取得了一定的进展,而化疗药物在维持治疗中维持治疗期的副反应发生率较高,靶向药物对EGFR野生型患者生存获益有待进一步研究。中医药维持治疗在提高生存质量、延长无进展生存期和/或总生存期方面可使患者获益。
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. It is a malignant tumor with high incidence rate and mortality rate. After the first-line chemotherapy for advanced NSCLC, some progress have been made in maintenance treatment consists of either chemotherapy or targeted therapy to stabilize the condition, before the drug resistance. However, there is a high incidence of various side reactions of maintenance chemotherapy. Further studies are needed to confirm the survival benefit of the patient with wild type EGFR genes. Traditional Chinese medical treatment on maintenance therapy offers great benefits to patients that include improve quality of life and prolong progression free survival and/or overall survival.
出处
《中医学》
2017年第1期12-18,共7页
Traditional Chinese Medicine
基金
上海市进一步加快中医药事业发展三年行动计划(ZY3-CCCX-3023)
上海申康医院发展中心临床科技创新项目任务(SHDC12016114)
国家中医药管理局国家中医临床研究基地业务建设科研专项(JDZX2012125)。
